DMAC vs. CLNN, IPA, APLT, VLON, BLPH, IMUX, HOOK, RZLT, FBIO, and SYRS
Should you be buying DiaMedica Therapeutics stock or one of its competitors? The main competitors of DiaMedica Therapeutics include Clene (CLNN), ImmunoPrecise Antibodies (IPA), Applied Therapeutics (APLT), Vallon Pharmaceuticals (VLON), Bellerophon Therapeutics (BLPH), Immunic (IMUX), Hookipa Pharma (HOOK), Rezolute (RZLT), Fortress Biotech (FBIO), and Syros Pharmaceuticals (SYRS). These companies are all part of the "pharmaceutical preparations" industry.
DiaMedica Therapeutics vs.
Clene (NASDAQ:CLNN) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, community ranking, media sentiment, analyst recommendations, dividends, profitability, valuation, risk and earnings.
DiaMedica Therapeutics has lower revenue, but higher earnings than Clene. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks.
DiaMedica Therapeutics received 39 more outperform votes than Clene when rated by MarketBeat users. However, 73.44% of users gave Clene an outperform vote while only 60.99% of users gave DiaMedica Therapeutics an outperform vote.
5.9% of Clene shares are owned by institutional investors. Comparatively, 28.1% of DiaMedica Therapeutics shares are owned by institutional investors. 26.6% of Clene shares are owned by insiders. Comparatively, 6.5% of DiaMedica Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Clene has a beta of 0.37, meaning that its stock price is 63% less volatile than the S&P 500. Comparatively, DiaMedica Therapeutics has a beta of 1.72, meaning that its stock price is 72% more volatile than the S&P 500.
In the previous week, Clene had 1 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 2 mentions for Clene and 1 mentions for DiaMedica Therapeutics. Clene's average media sentiment score of 0.94 beat DiaMedica Therapeutics' score of 0.00 indicating that Clene is being referred to more favorably in the media.
DiaMedica Therapeutics has a net margin of 0.00% compared to Clene's net margin of -5,151.64%. DiaMedica Therapeutics' return on equity of -46.58% beat Clene's return on equity.
Clene currently has a consensus target price of $10.33, indicating a potential upside of 903.24%. DiaMedica Therapeutics has a consensus target price of $10.00, indicating a potential upside of 218.47%. Given Clene's stronger consensus rating and higher possible upside, research analysts plainly believe Clene is more favorable than DiaMedica Therapeutics.
Summary
Clene beats DiaMedica Therapeutics on 10 of the 17 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding DMAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
DiaMedica Therapeutics Competitors List
Related Companies and Tools